Encore Preparing For Stimulan Bone Graft Substitute Launch In U.S.
This article was originally published in The Gray Sheet
Executive SummaryEncore Medical Corp.' s principle operating subsidiary, Encore Orthopedics, is poised to enter the bone void filler niche of the orthopedics products market with the Stimulan bone graft substitute.
You may also be interested in...
Steve Niedelman of the law firm King & Spalding gave manufacturers a few words of advice when prepping their so-called front rooms, where US FDA investigators do the majority of their work during facility inspections. See what he said here.
The latest figures from China's National Health Commission show infections of the new Wuhan coronavirus are continuing to pile up, spreading to more cities in the country and abroad as travel for the Lunar New Year festival goes into high gear. Meanwhile, the Chinese government maintains that the situation is “preventable and controllable.”